Ministry of Public Health Partners with GSK to Invest 1.5 Billion Baht in Clinical Research, Aiming to Make Thailand a Regional Vaccine Hub
Published
The Ministry of Public Health of Thailand has partnered with GSK, a global pharmaceutical and vaccine company, to propose an expansion of clinical research investment in Thailand. The total value is approximately 1.5 billion baht over a period of 10 years.
Under this plan, the collaboration will go beyond financial investment alone, also including the development of research personnel and improvements to the country's research system. This will help Thai researchers become better prepared to conduct clinical trials that meet international standards.
A key goal of the project is to push Thailand to become a center for vaccine research and development in Southeast Asia, which could help attract medical trials from abroad and increase access to medical innovations for the Thai people in the future.
However, this news is only a preliminary proposal. Details of implementation and a definite timeframe have not yet been disclosed in the news reports currently available.
Sources: LINE TODAY
More Thailand news
- Finalists Announced for “Best Digital News 2026” with 160 Works from 16 News Outlets
- Song and Bow Aim to Win the 2027 Thailand Volleyball League Championship
- Martian Dust Clings to Spacesuits, Potentially Posing Future Health Risks for Astronauts
- Thai national leads VC fund in Silicon Valley, opening doors for investors to access world-class Deep Tech
- Cabinet Approves Adjustment to Import Duty Criteria for Online Goods to Support Thai SMEs
- Prime Minister Opens Diwali 2026 Festival, Highlighting Thai-Indian Friendship and Promoting Thailand as a Global Cultural Tourism Destination
- Thai Political News for November 10, 2569
- AI and Open Data May Help Scrutinise Thailand's State Budget